BioPharmSignal logoBioPharmSignal

Biotech News

Spero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-CD40L Antibody

Spero Therapeutics (SPRO)Spero TherapeuticsClinical readout

Under the terms of the agreement, Spero will receive exclusive global rights, excluding Greater China, to develop, research, manufacture, and commercialize SP001 (IBI355)

Innovent will receive an upfront payment, and is eligible to receive development, regulatory and commercial milestone payments, totaling approximately...

Related news

SPROSpero Therapeutics2026-07-27 13:00 EST

Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer

ANTXAN2 Therapeutics2026-10-21 11:00 EST

AN2 Therapeutics to Present Phase 2 Design for Epetraborole in Polycythemia Vera at the 18th International Congress on Myeloproliferative Neoplasms

ANTXAN2 Therapeutics2026-11-04 12:00 EST

AN2 Therapeutics Advances Pipeline With Development Candidate Nomination for Hypophosphatasia (HPP)

SPROSpero Therapeutics2026-08-12 21:01 EST

Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update

SCYXSCYNEXIS2026-10-22 12:00 EST

SCYNEXIS Completes Phase 1 Study of Intravenous SCY-247, a Novel, Triterpenoid Antifungal in Development for Treatment and Prevention of Invasive Fungal Diseases

AVIRAtea2026-07-14 11:00 EST

Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus

ASMBAssembly Biosciences2026-10-29 20:00 EST

Assembly Biosciences Doses First Two Participants in Phase 2 Study of Oral NTCP Inhibitor ABI-6250 for Chronic Hepatitis Delta Virus

ENTAEnanta Pharmaceuticals2026-10-26 11:00 EST

Enanta Pharmaceuticals Announces First Patient Dosed in the RESOLVE Phase 2b/3 Study of Zelicapavir, a Potential First-in-Disease Treatment for Respiratory Syncytial Virus (RSV)

AVIRAtea2026-07-28 11:00 EST

Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus

ENTAEnanta Pharmaceuticals2026-06-18 11:00 EST

Enanta Pharmaceuticals Announces Advancement of its Zelicapavir Clinical Development Program for the Treatment of Respiratory Syncytial Virus (RSV)

View all latest news

Spero Therapeutics

Immunology and Inflammation Company Spero Therapeutics is a clinical-stage biopharmaceutical company developing medicines for serious immune-mediated diseases. Its internal strategy now centers on CD40 ligand inhibition. SP001 SP001 is a third-generation, Fc-silent monoclonal antibody targeting CD40 ligand. The molecule is designed to...

Recent company news

SPROSpero Therapeutics2026-11-04 22:05 EST

Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SPROSpero Therapeutics2026-11-02 22:05 EST

Spero Therapeutics to Present at Investor Conferences in November

SPROSpero Therapeutics2026-10-26 13:00 EST

Spero Therapeutics Strengthens Leadership Team to Advance Immunology Pipeline

SPROSpero Therapeutics2026-10-26 13:00 EST

Spero Therapeutics Strengthens Leadership Team to Advance Immunology Pipeline

SPROSpero Therapeutics2026-10-26 13:00 EST

Spero Therapeutics Strengthens Leadership Team to Advance Immunology Pipeline

Stock data

Close
1.02 USD
Market cap
163.86M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States